|
論文発表（2024年）
|
|
2024/00
|
The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation
|
|
Buttgereit T（Charité – Universitätsmedizin Berlin），Hide M，et al.
|
|
Clinical and Experimental Allergy
|
Vol.54 No. Page 712-716
|
|
2024/00
|
CRUSE® -An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria
|
|
Neisinger S（Charité – Universitätsmedizin Berlin），Hide M，et al.
|
|
Clinical and Translational Allergy
|
Vol.14 No. Page e12328
|
|
2024/00
|
Efficacy and safety of switching to bilastine, an H1-antihistamine, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a multicenter, open-label, randomized, parallel-group comparative study
|
|
Fukunaga A（Osaka Medical and Pharmaceutical University），Hide M，et al.
|
|
Frontiers in Immunology
|
Vol.15 No. Page 1441478
|
|
2024/00
|
Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus
|
|
Reshef A（Barzilai University Medical Center），Hide M，et al.
|
|
Journal of Allergy and Clinical Immunology
|
Vol.154 No. Page 398-411
|
|
2024/00
|
Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis
|
|
Kido-Nakahara M（Kyushu University），Hide M，et al.
|
|
Journal of Allergy and Clinical Immunology Global
|
Vol.3 No. Page 100317
|
|
2024/00
|
A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema
|
|
Petersen RS（University of Amsterdam），Hide M，et al.
|
|
Journal of Allergy and Clinical Immunology In Practice
|
Vol.12 No. Page 1614-1621
|
|
2024/00
|
Analysis of disease burden in patients with hereditary angioedema from Japan by patient-reported outcomes
|
|
Hide M，et al.
|
|
Journal of Dermatology
|
Vol.in press No. Page
|
|
2024/00
|
A Staphylococcus epidermidis strain inhibits the uptake of Staphylococcus aureus derived from atopic dermatitis skin into the keratinocytes
|
|
Hide M，et al.
|
|
Journal of Dermatological Science
|
Vol.113 No. Page 113-120
|
|
2024/00
|
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation
|
|
Soegiharto R（Utrecht University），Hide M，et al.
|
|
JAMA Dermatology
|
Vol.160 No. Page 927-935
|
|
2024/00
|
Survey of hereditary angioedema episodes and quality of life impairment through a patient-participatory registry
|
|
Morioke S（Hiroshima University），Hide M，et al.
|
|
Journal of Cutaneous Immunology and Allergy
|
Vol.7 No. Page 12626
|
|
2024/00
|
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
|
|
Maurer M（Charité – Universitätsmedizin Berlin），Hide M，et al.
|
|
Lancet
|
Vol.403 No. Page 147-159
|
|
2024/00
|
Analysis of questionnaire survey to determine worldwide trends in prescriptions of biologics for the treatment of unresponsive chronic urticaria
|
|
Rubeiz CJ（Cincinnati Children's Hospital Medical Center），Hide M，et al.
|
|
World Allergy Organization Journal
|
Vol.17 No. Page 100858
|
|
2024/00
|
Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2 and 3 of the randomized APeX-J Phase III trial
|
|
Honda D（Chiba University），Hide M，et al.
|
|
World Allergy Organization Journal
|
Vol.17 No. Page 100882
|
|
2024/00
|
【遺伝性皮膚疾患】遺伝性血管性浮腫
|
|
秀 道広
|
|
皮膚科
|
Vol.5 No. Page 42-50
|
|
2024/00
|
【蕁麻疹と蕁麻疹様紅斑】遺伝性血管性浮腫の鑑別・病態と治療薬の進歩
|
|
秀 道広
|
|
皮膚病診療
|
Vol.46 No. Page 586-593
|
|
2024/00
|
【IgEの最新情報】慢性蕁麻疹の病態における自己反応性IgEと抗IgE/抗IgE受容体自己抗体の役割
|
|
秀 道広
|
|
臨床免疫・アレルギー科
|
Vol.81 No. Page 244-251
|
English
